PFS Partners’s ResMed RMD Stock Holding History

PFS Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-49	Closed	-$9.29K	–	460
2024 Q2	$9.29K	Buy	49 +1	+2%	+$203	0.01%	280
2024 Q1	$9.59K	Sell	48 -21	-30%	-$3.85K	0.01%	285
2023 Q4	$11.9K	Hold	69	–	–	0.01%	251
2023 Q3	$10.2K	Hold	69	–	–	0.01%	243
2023 Q2	$15.1K	Buy	+69	New	+$15.4K	0.01%	217

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

PFS Partners's RMD Position: Q3 2024 in Review

PFS Partners sold out of ResMed (RMD) in Q3 2024, closing a stake of 49 shares — an estimated $9.29K sold.

PFS Partners first reported a position in RMD in Q2 2023 and held it in 5 quarters. The position peaked at $15.1K in Q2 2023. 801 funds tracked by Wall St. Rank hold RMD as of Q3 2024.

PFS Partners reported no remaining ResMed position as of Q3 2024 after selling out during the quarter.
PFS Partners sold 49 ResMed shares in Q3 2024, an estimated $9.29K.
PFS Partners first reported a position in ResMed in Q2 2023 and held it in 5 quarters.
PFS Partners's ResMed position peaked at $15.1K in Q2 2023.
801 funds tracked by Wall St. Rank held ResMed as of Q3 2024.

Based on PFS Partners's 13F filing for Q3 2024, filed 1 Nov 2024.